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ice-cold PBS. Cell lysis was initiated by addition of 100 µL RIPA buffer (Cell Signaling Technology) per well supplemented with phosphatase and protease inhibitor cocktails (Sigma) followed by incubation on ice for 30 min. Cells were then harvested by scraping and transferred into pre-cooled microcentrifuge tubes. Whole cell lysates were cleared by centrifugation at 14,000 x g/4 °C for 10 min and transferred into fresh, precooled microcentrifuge tubes. Protein concentrations were determined using the Pierce BCA protein assay (Thermo) as per manufacturer's instructions. Equal amounts of protein were separated by SDS-PAGE and transferred to Immobilon-FL PVDF membranes (Merck Millipore) using Pierce™ 1-step transfer buffer (Thermo) and the Pierce™ Power Blotter (Thermo). Membranes were washed for 5 min with ddH2O, blocked with Odyssey ® Blocking Buffer TBS (Li-Cor) for 1 h at room temperature and then incubated with primary antibodies diluted in Odyssey ® Blocking Buffer TBS overnight at 4 °C with gentle agitation. On the next day, the membranes were washed three times with TBS-T (50 mM Tris, 150 mM NaCl, 0.05% Tween 20, pH 7.4) for 5 min before being incubated with secondary antibodies diluted in Odyssey ® Blocking Buffer TBS for 1 h at room temperature with gentle agitation. Finally, the membranes were washed three times for 5 min with TBS-T and then scanned using an Odyssey ® CLx imaging system (Li-Cor 
Data Availability
The structures of Akt1 in complex with the inhibitors 15c and 16a have been deposited in the Protein Data Bank under PDB-ID 6S9X for 15c and PDB-ID 6S9W for 16a. 3D structural models for Augment are also available via QR-codes within the corresponding figures. [18] 
Synthetic procedures and compound characterization Common Procedure A: Pyrazinone cyclization
In a round bottom flask 1.0 eq. of the diketone and 3.0 eq. of an -amino carboxamide were dissolved in a solvent mixture of ethanol and acetic acid (20:1, 3 mL/mmol). The suspension was heated under reflux conditions for 24 h at 90 °C. The reaction mixture was treated with few mL of 5 M NaOH solution and stirred for additional 12 hours at rt. The solution was extracted with dichloromethane, the combined organic fractions dried over Na2SO4 and the solvent was evaporated in vacuo. The pure product was obtained after silica gel column chromatography (7 -10 % MeOH/DCM + 1 % NH3).
Common Procedure B: Boc deprotection
A solution of 1.0 eq. boc-protected amine was dissolved in 1,4-dioxane (5mL/mmol) and after addition of 4 N HCl in 1,4-dioxane (2.5 mL/mmol) the mixture was stirred for 12 h at room temperature. After completion, the reaction mixture was basified with 10 M NaOH solution. The resulting precipitate was separated and extracted with dichloromethane. The combined organic fractions were dried over Na2SO4 and the solvent was evaporated in vacuo. The pure product was obtained after silica gel column chromatography (7 -10 % MeOH/DCM + 1 % NH3).
Common Procedure C: Acrylamide coupling First 1.0 eq. of the aniline was dissolved in dry THF (10 mL/mmol), 3 eq. DIPEA were added and the solution was stirred for 15 min at 0 °C under argon atmosphere. Subsequently, a solution of 1.5 eq. acryloyl chloride in few mL THF was added dropwise. The reaction mixture was stirred at room temperature until completion. Afterwards the reaction was quenched with a saturated solution of NaHCO3. The aqueous layer was extracted with DCM and the combined organic layers were washed with saturated NaCl solution and dried over Na2SO4. The solvent was evaporated in vacuo and silica gel column chromatography yielded the desired product (7 -10 % MeOH/DCM + 1 % NH3). (2) . 5-Chloro-1-(piperidin-4-yl)-1,3-dihydro-2Hbenzo[d]imidazol-2-one (1, 2.5 g, 9.9 mmol) was stirred at 60 °C in 100 mL o-xylene. Then, 6 eq. of concentrated nitric acid (69 %) were added dropwise and the reaction mixture was heated for 1 h. The solvent was decanted and the residual crude product was washed with MeOH. Afterwards, the pure product was filtered off and yielded the title compound as pale yellow solid 2 ( 
Synthesis of 5-chloro-6-nitro-1-(piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one

Synthesis of tert-butyl
imidazol-2-one (3, 3.7 g, 15.9 mmol, 1.0 eq.) was stirred in 40 mL 1,4-dioxane (2.5 mL/mmol) and 10 % acetic acid. 1.5 eq. Boc2O (4.7 mL, 23.9 mmol) was dissolved in 10 mL 1,4-dioxane and then added dropwise to the reaction mixture, which was allowed to stir overnight at room temperature. The mixture was neutralised with 10 M NaOH and extracted with DCM. The combined organic fractions were dried over Na2SO4 and evaporated in vacuo. Silica gel column chromatography (7 - Synthesis of 1-methyl-4-(phenylethynyl)benzene (7) . Under argon atmosphere diisopropylamine (5 mL, 1mL/mmol) was degassed for 10 min and then iodobenze (546.4 µL, 4.90 mmol, 1.0 eq.), tetrakis(trisphenylphosphine)palladium(0) (7.0 mg, 0.05 mmol, 0.1 eq.) and copper(I)iodide (9.3 mg, 0.05 mmol, 1.0 eq.) were added subsequently. Then, tolylacytelene (704,1 µL, 5.88 mmol, 1.2 eq.) was added dropwise and the reaction mixture stirred for 12 h at 60 °C. (9) . The diketone 8 (0.39 g, 1.72 mmol, 1.0 eq.) and Nbromsuccinimide (0.34 g, 1.89 mmol, 1.1 eq.) were dissolved in tetrachloromethane (10 mL, 5.5 mL/mmol) and at last the initiator benzoylperoxide (60.0 mg, 0.34 mmol, 0.2 eq.) was added. (10) . Under argon atmosphere the boc-protected benzimidazolone 4 (0.39 mg, 1.18 mmol, 1.0 eq.) and the dione 9 (0.41 g, 1.42 mmol, 1.2 eq.) were dissolved in dry THF (15 mL, 12 mL/mmol). Then the base DIPEA (0.62 mL, 3.56 mmol, 3.0 eq.) was added and the mixture stirred for 3 h at rt. The resulting suspension was extracted with DCM and the combined organic fraction were washed with NaHCO3 solution. After drying with Na2SO4, filtration and evaporation of the solvents, a silica gel column chromatography was performed ( 
Synthesis of 1-(4-(bromomethyl)phenyl)-2-phenylethane-1,2-dione
Synthesis of tert-butyl
imidazol-5-yl)carbamate (10, 100 mg, 0.18 mmol, 1.0 eq.) and alanine carboxamide (88,1 mg, 0,54 mmol, 3.0 eq.) were used following common procedure A and yielded a mixture of the titled compounds as pale yellow solid (46 %). 
Synthesis of tert-butyl (3-(1-(4-(5-(4-hydroxybenzyl)-6-oxo
imidazol-5-yl)carbamate (10, 100 mg, 0.18 mmol, 1.0 eq.) and tyrosine amide (96.9 mg, 0.54 mmol, 3.0 eq.) were used following common procedure A and yielded a mixture of the titled compounds as a pale yellow solid (48 %). 
Synthesis
of 6-amino-1-(1-(4-(5-isobutyl-6-oxo-3-phenyl-1,6-dihydropyrazin-2-yl)benzyl)piperidin-4-yl)-1,3-dihydro-2H- benzo[d]imidazol-2-one (14b). Tert-butyl (3-(1-(4-(5-isobutyl-6-oxo-3-phenyl-4,5-dihydropyrazin-2-yl)benzyl)piperidin-4-yl)-2-oxo-2,3- dihydro-1H-benzo[d]imidazol-5-yl)carbamate (12b,
of 
.0 mg, 0.09 mmol, 1.0 eq.) and was used following common procedure B and yielded the titled compound as a pale yellow solid ( 
Synthesis of 6-amino
-1-(1-(4-(6-(4-hydroxybenzyl)-5-oxo-3-phenyl-4,5-dihydropyrazin-2-yl)benzyl)piperidin-4-yl)-1,3-dihydro-2H- benzo[d]imidazol-2-one (13c). Tert-butyl (3-(1-(4-(6-(4-hydroxybenzyl)-5-oxo-3-phenyl-1,6-dihydropyrazin-2-yl)benzyl)piperidin-4-yl)- 2-oxo-2,3-dihydro-1H-benzo[d]imidazol-5-yl)carbamate (
Synthesis
imidazol-2-one (13a, 21.0 mg, 0.04 mmol, 1.0 eq.) and was used following common procedure C and yielded the titled compound as a pale yellow solid (5.08 mg, 0.01 mmol, 23 %). 
of N-(3-(1-(4-(5-methyl-6-oxo-3-phenyl-1,6-dihydropyrazin-2-yl)benzyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1H- benzo[d]imidazol-5-yl)acrylamide (16a). 6-Amino-1-(1-(4-(5-methyl-6-oxo-3-phenyl-1,6-dihydropyrazin-2-yl)benzyl)piperidin-4-yl)-1,3- dihydro-2H-benzo[d]imidazol-2-one (14a,
Synthesis of N-(3-(1-(4-(5-(4-hydroxybenzyl)-6-oxo-3-phenyl-1,6-dihydropyrazin-2-yl)benzyl)piperidin-4-yl)-2-oxo-2,3-dihydro-1Hbenzo[d]imidazol-5-yl)acrylamide
(16c). 6-Amino-1-(1-(4-(5-(4-hydroxybenzyl)-6-oxo-3-phenyl-1,6-dihydropyrazin-2yl)benzyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one (14c, 31.0 mg, 0.05 mmol, 1.0 eq.) and was used following common procedure C and yielded the titled compound as a pale yellow solid (11.1 mg, 0.01 mmol, 33 %). Figure S1 . Sequence Alignment of the three Akt Isoforms. The Alignment was performed with Clustal Omega [1] and gave an overall identity of 73 %. The sequence of the PH Domain is coloured green and the secondary structure elements are indicated below the sequence (grey; tube --helix, arrow --sheet). Conserved amino acids in the sequence are marked below with (*), conservative mutations (:), semi-conservative mutations (.), and non-conservative mutations with ( ). Highlighted in red are the amino acids as well as secondary structure elements which form the inter domain binding pocket and presumably interact with the allosteric ligand. Figure S2 . Homology model of Akt2 (red) and Akt3 (yellow) based on Akt1 complex crystal structure 6HHI (white) generated with SWISS-MODEL. [2] Altered residues which are in close contact to the ligand (blue) within the allosteric binding pocket, are labelled exclusively (residue numeration are based on the Akt1 complex template). 28.20
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